Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai.
10.1007/s11684-022-0977-3
- Author:
Ziyu FU
1
;
Dongguo LIANG
1
;
Wei ZHANG
1
;
Dongling SHI
2
;
Yuhua MA
3
;
Dong WEI
4
;
Junxiang XI
1
;
Sizhe YANG
1
;
Xiaoguang XU
1
;
Di TIAN
2
;
Zhaoqing ZHU
2
;
Mingquan GUO
2
;
Lu JIANG
1
;
Shuting YU
1
;
Shuai WANG
1
;
Fangyin JIANG
1
;
Yun LING
2
;
Shengyue WANG
1
;
Saijuan CHEN
5
;
Feng LIU
6
;
Yun TAN
7
;
Xiaohong FAN
8
Author Information
1. Shanghai Institute of Hematology, National Research Center for Translational Medicine, State Key Laboratory of Medical Genomics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine, Shanghai, 200025, China.
2. Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China.
3. Department of Nephrology, Traditional Chinese Medicine Hospital of KunShan, Suzhou, 215300, China.
4. Department of Infectious Diseases, Ruijin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine, Shanghai, 200025, China.
5. Shanghai Institute of Hematology, National Research Center for Translational Medicine, State Key Laboratory of Medical Genomics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine, Shanghai, 200025, China. sjchen@stn.sh.cn.
6. Shanghai Institute of Hematology, National Research Center for Translational Medicine, State Key Laboratory of Medical Genomics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine, Shanghai, 200025, China. lf12034@rjh.com.cn.
7. Shanghai Institute of Hematology, National Research Center for Translational Medicine, State Key Laboratory of Medical Genomics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine, Shanghai, 200025, China. ty12260@rjh.com.cn.
8. Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China. fanxiaohong@shphc.org.cn.
- Publication Type:Journal Article
- Keywords:
COVID-19;
SARS-CoV-2;
bronchoalveolar lavage fluid (BALF);
host response
- MeSH:
Humans;
Aged;
Middle Aged;
COVID-19/prevention & control*;
SARS-CoV-2;
Pandemics/prevention & control*;
China/epidemiology*;
Disease Outbreaks/prevention & control*;
Vaccination
- From:
Frontiers of Medicine
2023;17(3):562-575
- CountryChina
- Language:English
-
Abstract:
The Omicron family of SARS-CoV-2 variants are currently driving the COVID-19 pandemic. Here we analyzed the clinical laboratory test results of 9911 Omicron BA.2.2 sublineages-infected symptomatic patients without earlier infection histories during a SARS-CoV-2 outbreak in Shanghai in spring 2022. Compared to an earlier patient cohort infected by SARS-CoV-2 prototype strains in 2020, BA.2.2 infection led to distinct fluctuations of pathophysiological markers in the peripheral blood. In particular, severe/critical cases of COVID-19 post BA.2.2 infection were associated with less pro-inflammatory macrophage activation and stronger interferon alpha response in the bronchoalveolar microenvironment. Importantly, the abnormal biomarkers were significantly subdued in individuals who had been immunized by 2 or 3 doses of SARS-CoV-2 prototype-inactivated vaccines, supporting the estimation of an overall 96.02% of protection rate against severe/critical disease in the 4854 cases in our BA.2.2 patient cohort with traceable vaccination records. Furthermore, even though age was a critical risk factor of the severity of COVID-19 post BA.2.2 infection, vaccination-elicited protection against severe/critical COVID-19 reached 90.15% in patients aged ≽ 60 years old. Together, our study delineates the pathophysiological features of Omicron BA.2.2 sublineages and demonstrates significant protection conferred by prior prototype-based inactivated vaccines.
